Shares of AstraZeneca PLC (AZN) surged 5.03% in pre-market trading on Thursday, following the company's impressive fourth-quarter results and optimistic guidance for 2025.
AstraZeneca reported a 24% year-over-year increase in total revenue for Q4 2024, reaching $14.89 billion, driven by robust growth across its key therapy areas, including Oncology (up 27%), Cardiovascular, Renal, and Metabolism (CVRM, up 16%), and Respiratory & Immunology (R&I, up 27%). The company's core earnings per share (EPS) jumped 44% to $2.09, surpassing analysts' expectations.
For the full year 2024, AstraZeneca's total revenue grew 21% to $54.07 billion, while core EPS increased 19% to $8.21. The strong performance was fueled by a 19% rise in product sales, continued growth in partnered medicines (Alliance Revenue), and the achievement of sales-based milestones (Collaboration Revenue).
Looking ahead, AstraZeneca provided an optimistic guidance for 2025, forecasting a high single-digit percentage increase in total revenue and a low double-digit percentage growth in core EPS, both at constant exchange rates. The company also announced plans to increase its annual dividend to $3.20 per share and boost capital expenditure by approximately 50% to support portfolio growth and build capacity for transformative technologies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。